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Pharmacokinetics, Pharmacodynamics, and
Immunogenicity of Infliximab in Pediatric Inflammatory
Bowel Disease: A Systematic Review and Revised
Dosing Considerations
Dwight A. Winter, Maria E. Joosse, yzSaskia N. de Wildt, §Jan Taminiau,
Lissy de Ridder, and Johanna C. Escher
ABSTRACT
Objectives: Infliximab (IFX), a monoclonal antibody directed against tumor
necrosis factor alpha is a potent treatment option for inflammatory bowel
disease (IBD). Dosing regimens in children are extrapolated from adult data
using a fixed, weight-based dose, which is often not adequate. While clinical
trials have focused on safety and efficacy, there is limited data on pharma-
cokinetic characteristics and immunogenicity of IFX in children. The
objective was to provide a systematic overview of current literature on
pharmacokinetic and immunogenicity of IFX in children with IBD, to assess
the validity of current adult to pediatric dosing extrapolation.
Methods: A literature search identified publications up to October 2018.
Eligibility criteria were study population consisting of children and/or
adolescents with IBD, report of IFX trough levels and/or antibodies-to
IFX, full text article or abstract, article in English, and original data.
Results: Initial electronic search yielded 2360 potentially relevant articles,
with 1831 remaining after removal of duplicates. An additional search
yielded another 202 potentially relevant articles. Of the 2033 retrieved
articles, 2000 articles were excluded based on title, abstract, or eligibility
criteria. Clearance of IFX was increased in young children and children with
extensive disease, leading to lower trough levels after extrapolated dosing of
5 mg/kg, antibodies-to IFX emergence, and subsequent reduced efficacy.
Conclusions: Adult to pediatric weight–based dosing extrapolation is often
inadequate. We provide several considerations for optimal dosing of IFX in
children and adolescents with IBD.
Key Words: inflammatory bowel disease, infliximab, pediatric,
pharmacodynamics, pharmacokinetics
(JPGN 2020;70: 763–776)
What Is Known
 Current infliximab dosing in children with inflammatory
bowel disease is extrapolated fromadults (induction schedule
of 5mg/kg at week 0, 2, and 6 and subsequent q8 week
maintenance infusions of 5mg/kg).
 During maintenance treatment, infliximab treatment is
aimed at reaching serum trough levels of 3 to 7mg/mL, as
associated with improved clinical outcome, reduction in
inflammatory markers, and endoscopic remission in both
pediatric and adult inflammatory bowel disease.
 Children and adolescents with extensive disease and high
disease activity (such as acute severe ulcerative colitis) often
have low serum albumin and increased infliximab clearance
necessitating induction doses >5mg/kg, aimed at reaching
infliximab serum trough levels of 5 to 10mg/mL at week 14.
What Is New
 Young children (younger than 11 years of age) have increased
infliximab clearance and require a dose>5mg/kg, or a dosing
interval shorter than 8 weeks, aimed to reach and maintain
adequate infliximab serum trough levels (>3mg/mL).
 In case of infliximab monotherapy, a dose >5mg/kg is
often required to reach and maintain adequate infliximab
serum trough levels.
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T umor necrosis factor alpha (TNF-a) is a key inflammatorycytokine involved in various inflammatory pathways. TNF-a
is detected in lesions in the intestine of patients with inflammatory
bowel disease (IBD, Crohn disease [CD], and ulcerative colitis
[UC]) (1) and has a pivotal role in IBD pathogenesis. Infliximab
(IFX), a chimeric IgG1 monoclonal antibody (75% human, 25%
murine), was developed in the early 1990s as the first anti-TNF-a
biological agent. IFX is effective in refractory IBD and has been
registered for use in children with CD and UC in 2007 and 2011,
respectively (Supplemental Fig. 1, Supplemental Digital Content,
http://links.lww.com/MPG/B781).
In adult literature increasing data suggest different thera-
peutic thresholds for IFX depending on the stage of therapy
(induction vs established maintenance) and treatment goal (ie,
clinical remission, endoscopic improvement) (2). Unfortunately
similar target levels are not yet established in the pediatric popu-
lation. In general both the administered dose of a monoclonal
antibody and its clearance are important to achieve a certain
target level.
In both children and adults with IBD, monoclonal antibodies
often display highly variable and complex pharmacokinetic (PK)
behavior with several factors influencing their clearance. IFX
clearance in IBD can be influenced by disease-related factors such
as disease severity (ie, local vs systemic inflammation), increased
intestinal permeability due to inflammation, or increased proteatic
activity and thus degradation of drug-TNF-a immune complexes in
inflamed tissue. In addition, the presence of antibodies-to IFX
(ATIs) and the use of concomitant immunomodulator (IM) are
known to influence clearance of IFX. In IBD, age per se has not
been established as an independent factor involved in IFX clear-
ance. Goldman et al (3) have, however, previously reported a
significant inverse association between age and IFX clearance in
juvenile idiopathic arthritis patients. Children younger than 7 years
of age had a 1.6-fold greater median clearance than children
ages 7 years or older (0.008 vs 0.005 L  kg1  day1, respectively;
r2¼ 0.21, P< 0.001).
Increased understanding of the variability of IFX clearance
has gradually shifted the focus to proactive measurement of IFX
trough levels (TLs) in children and adults also known as thera-
peutic drug monitoring (TDM). If age as an independent factor
can potentially influence IFX clearance, it should be taken into
account when administering IFX to younger patients with IBD.
Current dosing in children is, however, weight based and origi-
nally extrapolated from adults as justified by several small studies
suggesting initial similarity in PK between the different age
groups (4–8). In adult IBD, TLs of 3 to 7mg/mL are considered
adequate and are associated with improved clinical outcome,
reduction in inflammatory markers, and endoscopic remission
(9–15) (Fig. 1).
After more than 10 years of clinical experience with IFX
in pediatric IBD, there is reasonable doubt whether the linear
adult-to-pediatric extrapolation and dosing advice is still valid.
In practice, young children and children with severe acute colitis
often need higher doses to reach adequate TLs and achieve and
maintain clinical remission, as incorporated in the recent con-
sensus-based European Crohn’s and Colitis Organisation
(ECCO)-European Society for Paediatric Gastroenterology,
Hepatology, and Nutrition (ESPGHAN) guideline on acute
severe UC (16,17).
We provide a systematic overview of the literature cur-
rently available on pharmacodynamics (PD), and immunogenicity
of IFX in children and adolescents with IBD and assess the
validity of current weight-based dosing schedules. Finally, we
provide considerations for more optimal dosing of IFX in
pediatric IBD.
METHODS
Search Strategy
A literature search was performed to identify all published
studies that reported PK or PD data on IFX in children or adoles-
cents with IBD. An initial systematic search of the following
databases was performed up to February 12, 2016: Cochrane
Central, Ovid MEDLINE, Embase, Web-of-Science, PubMed
recent, and Google Scholar (see Appendix for detailed search
strategy, published online). In addition, reference lists of review
articles and selected articles were examined for additional eligible
studies. An additional search was performed in Embase on
October 18, 2018.
Inclusion and Exclusion Criteria
We included all studies (clinical trials, observational studies,
and cohort studies) that fulfilled the following criteria: study
population consisted of children or adolescents with IBD, report
of IFX-TLs and/or ATIs, full text article or abstract available, article
written in English, and original data available in article. Reviews,
case reports, case series, meta-analyses, editorials, practical sum-
maries or guidelines, and animal studies were excluded.
Data Extraction and Quality Assessment
Titles and abstracts found through the search strategy were
evaluated by 2 independent reviewers (D.A.W. and M.E.J.) for
potential eligibility, using predefined criteria as described above.
Full articles and abstracts were included when inclusion criteria
were met. Systematic review was performed according to the
PRISMA guidelines (18). Quality assessment was not performed
due to study heterogeneity. Any disagreements were resolved by
discussion. Key questions were formulated according to the
‘‘PICO’’ method. P [population]: in pediatric patients with IBD,
is; I [intervention]: weight-based IFXdosing according to extrapo-
lation from adults (so 5mg/kg); C [comparison]: compared to
dosing in real-life clinical practice; O [outcome]: effective and
safe in reaching adequate IFX TLs and inducing and maintaining
clinical and/or endoscopic response and remission. The following
data were retrieved from published reports: study population, design
of study, dose and dosing interval of IFX, TLs, type of assay used,
concentration of ATI, disease outcome, and concomitant
(IM) treatment.
Definition of Standard Infliximab Treatment
IFX is administered intravenously in a weight-based dose in
both pediatric and adult patients. In pediatric IBD, similar to adult
IBD, recommended use of IFX indicates a dosing schedule of 5mg/
kg as an induction regimen (infusions at weeks 0, 2, and 6) followed
by a maintenance regimen of 5mg/kg every 8 weeks in case of
clinical response. IFX therapy can be intensified by increasing the
dose, shortening the interval between infusions, or both if clinical
response is lost over time. The different assays to measure
IFX concentration and ATI status in serum are discussed in the
Supplemental content. In Supplemental Table 1 (Supplemental
Digital Content, http://links.lww.com/MPG/B781), the assay used
is listed per individual study.
RESULTS
The electronic search yielded 2558 potentially relevant
articles. An additional 11 articles were identified from reference
lists in review articles (19–24). After removal of duplicates, 2033
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FIGURE 1. Three hypothetical clinical scenarios and their influence on IFX pharmacokinetic (PK). Three hypothetical clinical scenarios and their
influence on IFX PK in patients with inflammatory bowel disease (IBD) with expected response in clinical disease activity during induction and
maintenance until week 24. IFX concentration is given on a log scale. The grey area indicates the therapeutic window between 3 and 7mg/mL. IFX
concentrations <3mg/mL are associated with increases of clinical disease scores and the inflammatory marker C-reactive protein (82). IFX
concentrations >3mg/mL are associated with sustained response (13), decrease in disease activity (83), and decrease in risk of treatment failure
(11). Disease activity is divided in remission, mild, moderate, and severe disease activity. Each arrow represents an IFX infusion. Response to IFX
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records remained, of which 1988 articles were excluded on the basis
of title or abstract. A total of 45 articles were retrieved for detailed
assessment (Fig. 2) of which 13 did not meet our inclusion criteria,
resulting in a total of 32 articles for review.
Of the 32 studies that were selected, 23 were full text
manuscripts and 9 were abstracts. Regarding study design, 4 were
randomized controlled trials (7,25–27), 2 were cross-sectional
studies (28,29), and 26 were cohort studies, of which 14 were
retrospective (23,30–42), 11 were prospective (19–21,24,43–49),
and 1 partially retrospective and prospective (22) as listed in
Supplemental Table 1 (Supplemental Digital Content, http://
links.lww.com/MPG/B781).
Study Population
In total 2386 patients were reported in the 32 included
studies. Ten of these studies included CD patients only, whereas
2 focused exclusively on patients with UC. Most included patients
FIGURE 2. Study selection and exclusion stages PRISMA flow diagram of study selection and exclusion stages. ATI ¼ antibodies-to IFX; IBD ¼
inflammatory bowel disease; IFX ¼ infliximab.
treatment: (A) a normal PK pattern in a patient responding to IFX treatment. IFX concentration remains above the therapeutic range minimum of
3mg/mL and leads to a decrease in clinical disease activity. Loss of Response to IFX treatment: (B) a PK pattern in a patient with antibodies-to IFX
(ATI) formation shortly after the induction phase. IFX concentration decreases below the therapeutic range minimum of 3mg/mL because of
higher clearance due to ATI formation. Clinical disease activity decreases initially, but increases after ATIs are formed. When ATIs are detected using
analytical assays, IFX treatment is stopped. Need to adjust IFX treatment: (C) an expected PK pattern in patients with factors that might decrease
IFX concentration such as young age, high disease severity, low albumin, or low body weight. Adjustment of dose (continued line) or interval
(interrupted line) increases IFX concentration above therapeutic minimum of 3mg/mL. Clinical disease activity increases after initial response. IFX
treatment adjustment leads to regain of response and less disease activity. IFX ¼ infliximab.
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had CD phenotype (n¼ 1763; 74%) followed by UC (n¼ 382; 16%)
and IBD-unclassified (n¼ 19; 1%). Three included studies did not
specify the ratio of disease phenotype (n¼ 222 patients; 9%).
Dose and Dosing Schedules
The majority of studies listed in Supplemental Table 1
(Supplemental Digital Content, http://links.lww.com/MPG/B781)
used a standard dosing regimen of 5 mg/kg as established in adult
trials in CD (ie, ACCENT I (5), ACCENT II (5,50), and SONIC
trials (51)) or UC (ie, ACT 1 (6) and ACT 2 (52)), except for 5
studies where higher doses were used (20,26,29,32,44). One study
reported on pediatric patients treated with an IFX biosimilar (41).
Pharmacokinetics
Induction Phase
Median IFX serum levels during induction phase (of infusion
at week 0, 2, and 6) were reported in several studies at different
timepoints and levels ranged from 19.3mg/mL (week 2), 10.9 to
14.5mg/mL (week 6), 17.6mg/mL (weeks 2 and 6 combined), 27 to
29mg/mL (week 8), 16.80mg/mL (week 10), and 5.9mg/mL (weeks
11–14), with 5 mg/kg dosing (20,25–27,30,41,43,49).
Maintenance Phase
During maintenance median serum TLs ranged from 1.9 to
11.8mg/mL, with IFX doses ranging between 5 and 15 mg/kg
administered in 5- to 12-week intervals (19,20,25,27,37,39–
44,46). Higher dose and shorter dosing interval led to higher
TLs (25,28). Mean serum levels also increased with increasing
IFX dose (4.0, 40.2, and 88.6mg/mL, 1 week after a single dose of 1,
5, and 10 mg/kg IFX, respectively) (26). The respective areas under
the curve (mean  SD) for the respective doses were 3192 1790;
23,852 9792; and 58,216 21,118mg/mL  h. Several studies
reported on IFX-TLs but did not specify when these were measured;
IFX-TLs in these studies ranged from 1.8 to 13.6mg/mL (23,29,35).
Only 3 studies described the biological half-life of IFX,
which is 9 to 11 days in 5 mg/kg dosing in both CD and UC
(Supplemental Table 1, Supplemental Digital Content, http://
links.lww.com/MPG/B781) (7,25,26). Hadigan et al (26) reported
that biological half-life of IFX increased (4.8, 9.3, and 9.5 days)
with dose of IFX administered (for 1, 5, and 10 mg/kg doses,
respectively).
Pharmacokinetics in Young Children
Articles were also reviewed on PK data for children younger
than 10 years of age, in agreement with the Paris classification
(category A1a). Eleven articles included IFX-TLs of children
within this age range. None of the articles presented PK data
specifically on these young children. One article specified the
number of patients younger than 10 years of age (n¼ 13, all patients
with CD) (49). One article reported an IFX-TL of 7.1mg/mL for
patients 6 to 11 years of age (25).
Factors Associated With Pharmacokinetics
Proposed factors likely associated with IFX PK in IBD were
age, weight, dose, presence of ATI, concomitant IM use, inflam-
mation, clearance, and albumin (Supplemental Table 1, Supple-
mental Digital Content, http://links.lww.com/MPG/B781). TLs
were consistently lower in younger pediatric patients with IBD
(25,29,37,43). Age was positively associated with IFX-TL in 1
study (b estimate¼ 0.31, P¼ 0.04; mean age 18.5 4.4 years) (29).
Week 6 TL was lower in patients with UC aged 6 to 11 years
compared to patients aged 12 to 17 years (7.1 vs 15.3mg/mL) (25).
IFX-TLs were an estimated 4 to 17mg/mL for a 100 mg dose
(n¼ 5), 5 to 40mg/mL for a 200 mg dose (n¼ 9), and 24 to
49mg/mL for a 300 mg dose (n¼ 3) (43). Authors only reported
total doses and related IFX-TL levels, but as all patients received
5 mg/kg, it can be deducted that patients receiving the lower doses
were the youngest. Young children with lower body weight had
significantly lower TLs at week 2 (P< 0.001) and week 6
(P¼ 0.0445). This also suggests lower exposures in younger chil-
dren while receiving body weight normalized doses. Finally,
median IFX-TL was statistically higher for patients above the
age of 17 years (P¼ 0.010) (37).
Several studies reported that TLs were inversely correlated
with inflammatory markers such as fecal calprotectin (43,44,48), C-
reactive protein (CRP) (19,29,40,42,44,46,48), and erythrocyte
sedimentation rate (32,40,42,48). In addition, serum albumin levels
and body weight are associated with IFX-TLs: children with lower
TLs had lower serum albumin levels and weighed less than children
with high TLs (25,39,40,42,44,48).
In adults, concomitant IM therapy is known to increase IFX-
TLs. We found conflicting data in children and adolescents. Most
studies addressed combination IFX þ IM treatment (such as
thiopurines, corticosteroids, and methotrexate) Concomitant IM
treatment varied between 10.8% and 100% of patients within
included studies (Supplemental Table 1, Supplemental Digital
Content, http://links.lww.com/MPG/B781). Ten studies examined
the association between IM use and IFX-TLs (25,28,29,32,33,
35,40,42,44,46). Recently Chi et al (29) reported that, after adjust-
ing for covariates such as age, body mass index, CRP, and erythro-
cyte sedimentation rate, mean IFX-TLs were significantly higher in
combination treatment (17.0 1.3mg/mL) versus initial IFX mono-
therapy (11.5 2.1mg/mL). In all other studies, use of IM when
starting IFX treatment (25,44,46) or IM use at the time of TL
measurement (28,32,33,35,40,42,44) did not result in higher TLs.
Singh et al (46) reported higher TLs in patients who received an IM
during start of IFX treatment compared to no IM at week 14 (6.8 vs
3.1mg/mL; P¼ 0.14) and week 54 (7.6 vs 3.45mg/mL; P¼ 0.29),
but this difference was not statistically significant. Importantly,
patients with TLs3mg/mL were using concomitant IM more often
compared to patients who had TLs <3mg/mL (94% vs 79%;
P¼ 0.06) (28). Taken together, concomitant IM treatment seems
to increase IFX levels, as in adults.
ATI prevalence between 0% and 47% was reported while
actual concentrations of ATI were reported in 11 studies
(19,20,23,25,28,30,31,38,41,42,44). The units used to express
ATI concentration were not uniform, probably because of the
use of different assays within these studies. Candon et al (30)
reported that compared to moderate ATI titers (1:100–1:2000),
high ATI titers (1:4000–1:8000) were more often associated with
infusion reactions. Time until ATI formation varied greatly within
our reviewed articles (7,21,22,30,32,33,36,38,39,43). In some stud-
ies, ATI were detected already during the induction phase with the
earliest report before the second infusion (21,22,30,33,43). In most
studies, ATI were detected during maintenance phase with the latest
ATI detection occurring 4.6 years after start of IFX (32).
IM combination therapy seems related to a lower risk of ATI
formation (22,28,29,31,38,46). Miele et al (31) reported that IM use
protected against high titers of ATI and possibly ATI formation.
Schatz et al (22) reported that in 4 patients with low ATI titers, ATI
disappeared after IFX dose escalation or reintroduction of azathio-
prine. Singh et al (46) reported an association between IM use
before week 14, and the lower number of patients positive for ATI
after 1 year of IFX therapy. Zitomersky et al (28) reported that
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previous IM use, but not IM use at time of IFX measurement,
correlated with lower concentrations of ATI. Chi et al (29) reported
that in multivariate analysis patients currently on combination
therapy had a lower risk of detectable ATI (9.5%) compared with
those on monotherapy (20.0%) in multivariate analysis (OR 0.3;
95% CI, 0.1–0.7; P< 0.01). Finally, Kansen et al (38) reported that
children receiving IFX monotherapy had a lower chance of remain-
ing ATI free at 12, 24, and 36 months after start of IFX compared to
children with continuous IM combination therapy (72.6%, 57.7%,
and 48.1% compared to 93.4%, 91%, and 91%, respectively). Taken
together, data suggest a protective role for IM combination therapy
against immunogenicity of IFX, by lowering the risk of
ATI formation.
Several studies reported an inverse relationship between ATI
and TLs (20,21,28,37,48). One study reported that TLs measured at
week 14 may have a predictive value for occurrence of ATI at
week 54 after start of IFX (21). Emergence of ATIs was associated
with loss of response (22,30,33,34,37,38), duration of therapy
(39,49), and progression to surgery (28). There was no apparent
association between patient age and ATI prevalence (24,31),
although Miele et al suggested a protective role for young age in
the formation of ATI. This association was, however, not statisti-
cally significant in the limited number of patients examined
(n¼ 34).
Clinical Outcome: Pharmacodynamics
In adults, multiple studies have been conducted on the
relationship between IFX-TLs and clinical outcome. Currently
there is, however, no well-defined optimal threshold for IFX-TL.
In their guideline on TDM in adults with IBD, the American
Gastroenterological Association suggests an IFX-TL of 5mg/
mL during maintenance as a beneficial threshold based on the
proportion of patients not in remission compared to other thresholds
(IFX-TL 1mg/mL, 25% not in remission; 3mg/mL, 15% not in
remission; 5mg/mL, 8% not in remission; 7 or 10mg/mL, 4%
not in remission) (53,54). A cross-sectional retrospective study in
patients with CD with perianal fistulas by Yarur et al (55) reported
that an IFX-TL 10.1mg/mL may improve outcome, specifically
increasing the chance of achieving fistula healing (P¼ 0.012). In
addition, an IFX-TL <10.1mg/mL was associated with lack of
mucosal healing (P¼ 0.01).
Several pediatric studies related TLs to clinical outcome
(Table 1). More than half of the studies demonstrated a significant
association between high IFX-TLs and beneficial clinical outcome
(21,25,32,34,37,39,40,42,46,47,49). High TLs were associated with
high rates of clinical response (92.9%), clinical remission (64.3%),
and mucosal healing (92.9%), although the authors did not specify a
cut-off for TLs (25). Two studies did suggest optimal cut-off IFX
thresholds for ongoing IFX therapy at 12 months (49) (IFX-TL
9.10mg/mL at week 10) and deep remission (clinical remission
with normal CRP) at week 54 (21) (IFX-TL5.5mg/mL at week 14).
Van Hoeve et al (42) reported that median TLs during
maintenance treatment were significantly higher in children in
clinical, biological, and endoscopic remission compared to patients
not in remission. Two studies reported that week 14 TLs may have
predictive value for clinical remission without dose intensification
during maintenance or deep remission (clinical remission with
normal CRP) (21,46). Hofmekler et al (37) defined clinical outcome
as the need for dose optimization and reported that 37% of children
who required dose optimization had low TLs during maintenance
(<3mg/mL). Stein et al (49) reported that children who were still on
IFX treatment after 12 months had higher 10-week median TLs
compared to patients who had stopped IFX treatment. El-Matary
et al reported a significant correlation between higher TLs at
week 14 and healing of fistulizing perianal CD at week 24. At
week 14 IFX-TL in patients with CD with healed fistulae or fistulae
in the process of healing (ie, decrease or cessation of fistula
drainage) was significantly higher compared to the nonresponsive
perianal CD group (12.7 vs 5.4mg/mL; P¼ 0.02) (47). In summary,
data suggest an association between high TLs and beneficial clinical
outcome. Only 2 pediatric studies suggested IFX-TL thresholds for
optimal outcome.
DISCUSSION
In this review, we investigated the literature currently avail-
able on IFX PK and immunogenicity in children and adolescents
with IBD. In 2015 to 2016, position papers from the ESPGHAN, the
ECCO, and the global Pediatric IBD Network emphasized the
importance of assessing PK, PD, and safety in the pediatric IBD
population (56,57). We demonstrate that there are insufficient PK
studies in pediatric IBD, and that the available studies were con-
ducted in only a limited number of patients. Consequently there is
not enough evidence to support adult-to-pediatric extrapolation
concerning IFX dosing.
Historically, clinical trials in children and adolescents were
initiated long after approval of IFX for adults (Supplemental Fig. 1,
Supplemental Digital Content, http://links.lww.com/MPG/B781).
At that time, PK and PD were assumed to be similar for all age
groups, resulting in all-age weight-based dosing. Not only body
weight, but also growth and maturity, disease extent, serum albumin
levels, and formation of ATIs are all, however, important in the
systemic disposition of IFX (58–60).
In general, the optimal therapeutic thresholds for IFX remain
very much the subject of investigation. The optimal threshold can
vary because of per-patient differences in phase of therapy, disease
activity, and/or treatment goal. For instance, the American Gastro-
enterological Association suggested an optimal threshold of 5mg/
mL during maintenance in all patients with IBD based on proportion
of patients not in remission (53,54). If the goal is to achieve fistula
healing an IFX-TL 10.1mg/mL has been suggested. An IFX-TL
<10.1mg/mL was associated with lack of mucosal healing (55).
In our reviewed articles, 2 studies suggested optimal cut-off
IFX thresholds, that is, for ongoing IFX therapy at 12 months (49)
(IFX-TL 9.10mg/mL at week 10) and for deep remission (clinical
remission with normal CRP) at week 54 (21) (IFX-TL 5.5mg/mL
at week 14). Recently, data from a large prospective cohort study by
Kennedy et al (2) known as the personalized anti-TNF therapy in
CD study (PANTS) was published in the Lancet in which the
authors included both adult (n¼ 1391; 86.4%) and pediatric
(n¼ 219; 13.6%) patients with CD treated with IFX. Interestingly,
these data support a higher target IFX concentration than previously
thought, both during induction and maintenance (30–35mg/mL at
week 6 for week 14 remission and 7mg/mL at week 14 for week 54
remission, respectively). Continued prospective cohort research on
IFX TLs in relation to clinical outcome will provide more well-
defined recommendations in the future.
It is known from adult IBD literature that IFX clearance is
associated with disease severity (10,61,62). The extent and severity
of mucosal inflammation in children with IBD is reflected by the
clinical need for dose escalation in this population, to achieve
increased IFX serum concentrations above the therapeutic lower
threshold (63). Hypothetically, these patients may benefit from
higher initial IFX dosing during induction for maintenance of
adequate IFX serum concentrations and thus IFX treatment
(Fig. 1C). To maintain response children and adolescents with
IBD more often require dose escalation or interval shortening in
the first year of IFX treatment compared to adults (50%–57% vs
23%–46%, respectively) (7,64–66). In addition to the need for
higher dosing in case of increased clearance in acute severe
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pediatric UC, current ECCO-ESPGHAN guidelines also advise to
aim for higher TLs (5–10mg/mL) during maintenance treatment
and thus suggest an IFX intensified induction dose (dosing between
5 and 10 mg/kg is suggested). In addition, the authors suggest TDM
of IFX-TLs during induction to maximize efficacy (16).
Despite the lack of evidence in IBD, we suspect that IFX
clearance is inversely related to age (ie, higher clearance in younger
children) similar to findings by Goldman et al (3) in patients with
juvenile idiopathic arthritis. TLs increase with dose and the IFX
level profile in children shows a pattern similar to adults during
induction and maintenance (Fig. 1A) (4,7,8). Several pediatric
studies, however, reported TLs below the therapeutic range with
a standard 5 mg/kg dose at an 8-week interval (25,27). Four studies
comparing different age groups showed TLs to be lower in younger
children with IBD compared to adolescents (25,29,37,43).
Data suggest that there is an association between young age
and a decrease in IFX exposure, that is, in a pediatric patient with IBD
receiving standard treatment IFX-TLs are lower compared to an adult
patient with IBD with similar disease burden. It would be interesting
to determine at what age pediatric PK and adult PK begin to show
more resemblance. Unfortunately current available data do not yet
enable us to answer this question. It is important to acknowledge that
the aforementioned association between younger age and increased
clearance might be an oversimplification. Because younger children
tend to have more colitis with extensive disease, disease severity (ie,
extent and location) may be a confounding factor.
Reported prevalence of ATI in the pediatric population is
comparable to adult data as reviewed by Lichtenstein et al (67).
ATI formation increases IFX clearance, thereby lowering TLs and
IFX efficacy. The potential effects of ATI formation on PK and
clinical disease activity are schematically represented in
Figure 1B. On the contrary, achieving higher IFX-TLs by increas-
ing IFX dose or dosing interval can potentially prevent ATI
formation (Table 2), because in adults both prolonged low IFX-
TLs and low IFX-TLs at week 14 may precede ATI formation
(68,69). Similarly to adult data, Rosenthal et al (21) reported an
inverse association between IFX-TL at week 14 and ATIs at
week 54 (P¼ 0.003) in pediatric patients with IBD. Several studies
reported a reduction of ATI formation and ATI concentration with
concomitant IM therapy, and an increase of IFX-TL. Interestingly,
van Hoeve et al (42) did report a significant clinical and biological
benefit from combination therapy.
Other factors in children and adolescents associated with low
TLs were low albumin, low body weight, and high inflammatory
markers (19,25,29,32,39,40,43,44,46,48). These are all factors that
could potentially lead to increased clearance, as shown in adults
(25,44,70). In older children, median biological half-life (6,7,25)
and overall clearance (71) of IFX are reported to be similar to the
adult population. In summary age, albumin, body weight, and the
presence of inflammatory markers all seem associated with IFX
clearance within the pediatric IBD population.
The strength of this systematic review is that it consists of a
comprehensive overview of articles with original data on IFX PK
and PD in children and adolescents. Several pediatric studies
observed an association between IFX exposure and clinical
response, similar to studies in adults. In addition, IFX-TLs were
related with multiple factors including disease severity, age, pres-
ence of ATI, and clearance. Taken together, there is enough
evidence to suggest that a proportion of pediatric patients will
not achieve adequate IFX-TLs using weight-based dosing, but
rather would benefit from individualized dosing which could result
in a higher dose and/or shorter dosing interval. PK effects of therapy
adjustment can be monitored by frequent measurement of IFX-TLs,
also known as TDM. Figure 1C schematically represents the
hypothetical PK profile of IFX in relation to clinical disease activity
for patients that require adjustment of initial standard IFX treat-
ment. Although analytical tests to determine IFX concentrations or
ATIs are not standardized, several authors have reported good
correlation between enzyme-linked immuno sorbent assays
(ELISA), and electro-chemiluminescence immunoassays (ECLIA)
and ELISA from different manufacturers (72–74). A greater greater
understanding of how to interpret IFX PK data from different assays
will improve comparability of their respective results. At present,
efforts are also focusing on developing new assays that can improve
on the speed of current assays used in TDM by measuring IFX
concentrations or ATIs in dry blood spots or whole blood instead of
serum. One such new assay using fiber optic surface plasmon
resonance technology seems to generate data comparable to current
ELISA assays (75). Novel assays could potentially speed up the
TDM process from a current 2 hours to 1.5 days minimum to 20
minutes. More and more, proactive TDM is incorporated in clinical
care to optimize treatment in the pediatric population. The possi-
bility of point-of-care TDM by the development of new techniques,
could benefit patients, and decision making by treating physicians.
Limitations of the current systematic review concern the
limited number of small studies in children and their variable design
and lack of standardization in measurement of IFX and ATI
concentration. An accurate quantification and comparison of ATI
concentration between studies is most difficult since ELISA assays
do not detect ATIs in the presence of IFX. Care needs to be taken
when comparing IFX-TLs and ATI levels. The small sample size of
most studies (<n¼ 100 in 25/32 studies) make statistical analyses
less reliable and complicate any comparison with adult PK data, as
derived from larger patient samples. Despite these limitations the
reported associations between IFX-TL and ATIs, and disease
severity, disease extent, (prior) IM use, inflammatory markers,
albumin, body weight, and age are still relevant. Although most
TABLE 2. Dosing and drug monitoring considerations for clinicians
treating children and adolescents with infliximab
– Maintaining adequate IFX serum trough levels above the therapeutic
lower limit of 3mg/mL in children and adolescents is important for
clinical efficacy of IFX and may also protect against the formation of
antibodies-to-infliximab (ATIs).
– Treatment with concomitant immunomodulatory (IM) therapy during
the induction phase of IFX treatment is advised, to prevent the
formation of ATIs, and to increase the IFX serum concentration in
children and adolescents.
– In case of IFX monotherapy in children and adolescents, a dose >5 mg/
kg or a shortening of interval between IFX infusions might be required
to reach and maintain adequate IFX serum trough levels above the
therapeutic lower limit of 3mg/mL. Frequent trough level
measurement (therapeutic drug monitoring) is advised
– Young children (<11 years of age) are more likely to require a dose >5
mg/kg IFX or a shortening of interval between IFX infusions to reach
and maintain adequate IFX serum trough levels above the therapeutic
lower limit of 3mg/mL. Frequent trough level measurement
(therapeutic drug monitoring) is advised
– In children and adolescents with high disease severity (such as severe
acute colitis), an initial dose>5 mg/kg IFX or a shortening of interval
between IFX infusions should be considered to reach adequate IFX
serum concentrations. Recent guidelines suggest that the therapeutic
window in these patients is possibly between 5 and 10mg/mL.
– In children and adolescents with low albumin concentrations, an initial
dose>5 mg/kg IFX or a shortening of interval between IFX infusions
should be considered to reach adequate IFX serum concentrations
above the therapeutic lower limit of 3mg/mL.
IFX ¼ infliximab.
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factors show trends similar to the adult population, there are unique
differences such as the association between low TLs and young age
and the more frequent occurrence of therapy escalation in children
and adolescents with IBD.
Examining these distinctive factors will prove helpful in
clarifying PK and PD differences in children and adolescents com-
pared to adults. Large prospective cohort studies such as the recent
PANTS study (2) have the potential to clarify these and other
important questions regarding IFX PK, PD, and safety going forward.
On the basis of this review, we propose several considerations for
more optimal dosing of IFX in the pediatric population (Table 2).
CONCLUSIONS
In summary, literature with data on IFX PK or immunoge-
nicity in children and adolescents is limited. From the included
studies in this review, we conclude that current practice of extrapo-
lation from adult experience to pediatric treatment is not valid.
Currently, pediatric PK studies are too few and also lack statistical
power to prove similarity of PK and PD between children and
adolescents, and adults. Available literature shows increased IFX
clearance specifically in young children and children with more
severe disease. Especially in these cases, loss of response and/or
need for frequent therapy adjustment is common when adult-
extrapolated, weight-based dosing is used. Patients with increased
clearance will need higher dosing of IFX to reach ‘‘standard’’ TLs
(3–7mg/mL). In addition, recent ECCO-ESPGHAN guidelines
recommend aiming at higher IFX-TLs (5–10mg/mL) in severe
acute UC patients, while stressing the importance of TDM. To
further improve therapeutic strategies in the pediatric population
utilizing IFX, or any other newly developed biological drug, easy-
to-use dashboard systems that combine data from existing PK
models with patient information acquired from TDM and patient
factors, can help to further optimize individual IFX dosing. Well-
designed studies on the PK properties in the pediatric population, as
well as implementation of proactive TDM can contribute to the
advancement of these dashboard systems and improve on individ-
ualized therapeutic strategies in the future.
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